Meyer 2017 (PROVE).
Study name | Long‐term Prophylaxis of Venous Thromboembolism with low‐molecular‐weight heparin in patients with metastatic lung cancer |
Methods | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Outcomes Assessor Primary Purpose: Prevention |
Participants | Adult patients aged ≥ 18 years with stage IV lung cancer and elevated D‐dimer |
Interventions | Intervention: Tinzaparin sodium subcutaneous tinzaparin 4,500 IU once daily for six months. Control: No intervention‐ usual care |
Outcomes | All VTE events (symptomatic and asymptomatic PE and DVT) Major bleeding Death |
Starting date | April 2017 |
Contact information | Guy Meyer, MD +31 156 093461 guy.meyer@aphp.fr |
Notes | Status as of August 2017: This study is not yet open for participant recruitment. |